We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New Assay Enables Creation of Customized miRNA Panels

By HospiMedica staff writers
Posted on 12 Dec 2007
miRNAs are becoming increasingly important in screening, diagnosis, and therapy. More...
A new assay has been developed that allows scientists to create customized microRNA panels. This enables more focused analysis of small subsets of microRNAs, which is essential to understanding more about the role microRNAs play in disease.

Until now, miRNA expression studies have been conducted on a global scale, resulting in unnecessary data overload. Extensive expression studies have repeatedly shown that miRNA expression is specific to various experimental systems including tissues and cellular pathways. Application-specific subsets of miRNAs, which usually consist of fewer than 50 miRNAs, can be used to analyze larger numbers of samples to further investigate or validate potential miRNA markers.

The miRNA platform is designed for both broad panel screens and smaller target validations. FleximiR Select is the latest in Luminex's (Austin, TX, USA) FlexmiR line of products. FlexmiR Select allows scientists to configure customized miRNA panels for their specific needs and provides the flexibility to mix and match up to 50 different miRNA probes in a single well.

Unlike conventional miRNA test methods, FlexmiR miRNA assays do not require enrichment or amplification; therefore they are simpler, faster and more reproducible than competing technologies.

"FlexmiR has enabled our lab to generate high quality data for our craniofacial bone development studies in less time compared to other technologies we have used,” said Dr. Winston Patrick Kuo, director of laboratory for innovative translational technologies at Harvard School of Dental Medicine (Boston, MA, USA). "A better understanding of both normal and abnormal intramembranous bone development will be paramount to the advancement of future diagnoses, treatments, and prevention of many craniofacial disorders.”


Related Links:
Luminex

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Spirometry & Oximetry Software
MIR Spiro
Pulmonary Ventilator
OXYMAG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.